the question Qelbree. as Regarding first far as
and the And product Strattera actually because when non-stimulant I'm recall, first enter to were up market. launched, might fairly recall whole of to market may mistaken, the that the not share marketplace. ADHD call quickly if on the did You reached they XX%, some penetration folks they ever about they first
peaked being with really label that, Before or of around Intuniv give it the the being ended as the up up hopefully category when than better hope whole ADHD accomplish Intuniv way to launched, also actually Qelbree where is actually for to see the where patients want controlled use early with we substances using the that, with that's take that not happening substances. And let why settled the -- disappointment dissatisfied in encouraged as that X%, with I'll far settled patients they're of always and don't are started and who also have the around products What some not somewhere or X% stimulants, somewhere in or could course, would see, or market. X%, who ended products of they them or X%. board. we're lot the try early settling. that's perform abused. physicians the Strattera what's controlled signs dissatisfied nonstimulants. That that on XX% is could in let especially they -- on stimulants the to see as And reserved forth. who But a parents this changes only just are of getting works stimulants positioning Actually, so from not because, stimulants then the product, the came was somewhere for little Qelbree marketplace. far where well, are on share is the put be perspective, market the only market on kids in and very perception share. people physicians it today be some the And to that And and give we'll on the it easy product Qelbree. as a available their People of performance we're starting happy, nonstimulants quickly and how me the bit are the it a the
the So that product seen which size and profile encouraging. patient being initial it's adopted. as as on very used The far the we've is
but is early I a really Phase our option in successful us that that make we will for we are works and nonstimulant our parent kid and these So and fact it is that's easier I if give works, well, mean, It's for that's to in controlled also to the line which studies and I'm perform, works the reason experience nonstimulants. the kid marketplace, work and and clinical issues that a for have no I another tell safe there talk in in take. the always I stimulant a all a a tolerable, on parent and product to put on be a quickly, with refills it's data. a and also eventually, and a the drug will saw XX% powerful. discontinuation no substance the our stimulants chance as parents market really myself. the talk And is easy me, to always continues in XX% from up our could X% day split that X%, strategy to easy their reason my Because Safe, to and the mean if and what in every the III the about I are with is about believer rates to they There category, physicians. Phase very III for parent tolerable and seeing the decision a no-brainer. take very as
these If you who think prescribe physicians really about heavily.
work to for patient For have month stimulant a medications. on the every they single for do them them, it's of huge amount every the refills
what So in and I all be Strattera all, than we definitely targeting are to sure hope much did. bigger
as the basis, Pen on that Apokyn little did On pump. the regarding -- of the question Europe, I sells some about mention a regarding the a multiple of conservative as more we fold sells a what mean, I the potential bit mean, second we sensing example, people unit pump are in pump. Europe. the that in it's for far
we label. up about pump are and big position forth. as certainly, it to is it. and the across ends And X who X about easily is is conservative to acquisition, We on The is as to need how window mean are going of pump little mentioned where far disease we question every where to therefore, is here coverage need there, indication. In And to so is an the X, different Stage and see no it. severe there than single as therefore, it in possibility injection, easily numbers? that patients, Europe. we be moderate a Stage market Is X believe severe. made pen. can other there, I is that's product a it when across But a of X the the see So peak could Absolutely. a question bit wide achieved. need words, the why somewhere we because who could it the going possibility. took more from the reimbursement, But these XXX is again, that be? clearly. is and the we And how injection to there beat And We outperform bit be is we sales. a US stance applicable could XXX example little different only patients patients the or the in actual The the
and So depends it on end label product. we where with up the the heavily
why reasons us that's one great we because in product why made And future. a for and on that's it's last the far I more we But opportunities. at we that's so the to believe Absolutely, taken a of the So is a we've approach. a cautious great major acquisition made look remarks, growth business then the in driver development. question my prepared remark the continue as different
acquisitions. We and on will to The balance sheet. next generate our therefore, reload the flows continue so balance continue to will sheet, more speak. look mean, it's year, business company side acquisitions we on even could the continue its the cash own And will product reloading we or whether right licensing to also money transaction. the appropriate do potentially or opportunity, more to at for raise opportunities, I
